首页> 美国卫生研究院文献>International Archives of Allergy and Immunology >Definitions Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal
【2h】

Definitions Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal

机译:肥大细胞疾病的定义标准和全球分类特别参考肥大细胞激活综合征:一项共识性提案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of ‘MCA syndromes’ (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D2, or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.
机译:组织肥大细胞(MCs)的激活及其在各种器官中的异常生长和积累通常在原发性MC疾病(也称为肥大细胞增多症)中发现。但是,现在越来越多的患者被告知,他们的临床发现是由于MC激活(MCA)引起的,而MC激活既与肥大细胞增多无关,也与明确的过敏或炎症反应无关。在其他MCA患者中,MC似乎是克隆细胞,但不符合诊断肥大细胞增多的标准。 2010年组织了一次工作会议,旨在确定诊断MCA和相关疾病的标准,并提出所有MC疾病和病理性MC反应的全球统一分类。此分类包括三种类型的“ MCA综合征”(MCAS),即原发性MCAS,继发性MCAS和特发性MCAS。现在,MCA由健全且普遍适用的标准定义,包括(1)典型的临床症状,(2)血清总类胰蛋白酶水平显着暂时升高,或其他MC衍生介质(例如组胺或前列腺素D2)或其尿代谢产物,以及(3)临床症状对减弱MC介体产生或活性的药物的反应。这些标准应有助于鉴别和诊断MCAS患者,并避免在日常操作中误诊或过度解释临床症状。此外,MCAS概念应促进研究,以便识别和利用新的分子机制和治疗靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号